Clinical Trial Approval For The Company's Novel Adjuvanted Recombinant Shingles Vaccine REC610 In The Philippines
- Written by PR Newswire
![]() |
TAIZHOU, China, Dec. 19, 2022 /PRNewswire/ -- Jiangsu Recbio Technology Co., Ltd. (the "Company", together with its subsidiaries, the "Group") is pleased to announce that, the Group has recently received the clinical trial approval for its novel adjuvanted recombinant shingles vaccine, REC610, from the Food and Drug Administration of the...















